NCT06025409View on ClinicalTrials.gov

Evaluate the Efficacy and Safety of DWJ108J

PHASE3UnknownINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

August 1, 2023

Primary Completion Date

February 28, 2025

Study Completion Date

August 31, 2025

Conditions
Central Precocious Puberty
Interventions
DRUG

Leuprolide Acetate 11.25 MG/ML

Subcutaneous injection

Trial Locations (1)

Unknown

RECRUITING

Ajou University medical center, Gyeonggi-do

Sponsors
All Listed Sponsors
lead

Daewoong Pharmaceutical Co. LTD.

INDUSTRY